POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink enlarged spleens in myelofibrosis patients
Disease control Recruiting nowThis phase 3 study tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for adults with myelofibrosis (a bone marrow disorder). About 460 people who have not taken JAK inhibitors before will receive either the combination or a place…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
5,000 patients join Long-Term study to unlock mysteries of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term observation of 5,000 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, insurance data, and patient surveys over at least five years to track symptoms, treatments, and how the disease …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:04 UTC